Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research

D. Buchbinder; R. Brazauskas; K. Bo-Subait; K. Ballen; S. Parsons; T. Johns; T. Hahn; A. Sharma; A. Steinbergs; A. D'Souza; A.J. Kumar; A. Yoshimi; B. Wirk; B. Shawl; C. Freytes; C. LeMaistre; C. Bredeson; C. Dandoy; D. Almaguer; D.I. Marks; D. Szwajcer; G. Hale; H. Schouten; H. Hashem; H. Schoemans; H.S. Murthy; H.M. Lazarus; J. Cerny; J. Tay; J.A. Yared; K. Adekola; K.R. Schultz; L. Lehmann; L. Burns; M. Aljurf; M.A. Diaz; N. Majhail; N. Farhadfar; R. Kamble; R. Olsson; R. Schears; S. Seo; S. Beattie; S. Chhabra; B.N. Savani; S. Badawy; S. Ganguly; S. Ciurea; S. Marino; U. Gergis

doi:10.1016/j.bbmt.2019.11.003

Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research

D. Buchbinder^*, R. Brazauskas, K. Bo-Subait, K. Ballen, S. Parsons, T. Johns, T. Hahn, A. Sharma, A. Steinbergs, A. D'Souza, A.J. Kumar, A. Yoshimi, B. Wirk, B. Shawl, C. Freytes, C. LeMaistre, C. Bredeson, C. Dandoy, D. Almaguer, D.I. MarksD. Szwajcer, G. Hale, H. Schouten, H. Hashem, H. Schoemans, H.S. Murthy, H.M. Lazarus, J. Cerny, J. Tay, J.A. Yared, K. Adekola, K.R. Schultz, L. Lehmann, L. Burns, M. Aljurf, M.A. Diaz, N. Majhail, N. Farhadfar, R. Kamble, R. Olsson, R. Schears, S. Seo, S. Beattie, S. Chhabra, B.N. Savani, S. Badawy, S. Ganguly, S. Ciurea, S. Marino, U. Gergis

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.

Original language	English
Pages (from-to)	553-561
Number of pages	9
Journal	Biology of Blood and Marrow Transplantation
Volume	26
Issue number	3
DOIs	https://doi.org/10.1016/j.bbmt.2019.11.003
Publication status	Published - 1 Mar 2020

Keywords

adolescent
aya
bone marrow transplantation
cancer survivors
care
childhood
health
intervention
lost to follow-up
outcomes
prevalence
stem cell transplantation
survivor
transition
Bone marrow transplantation
Stem cell transplantation
AYA
PREVALENCE
CARE
CANCER SURVIVORS
ADOLESCENT
HEALTH
INTERVENTION
Survivor
CHILDHOOD
TRANSITION
Lost to follow-up
OUTCOMES

Access to Document

10.1016/j.bbmt.2019.11.003Licence: CC BY-NC-ND

Cite this

Buchbinder, D., Brazauskas, R., Bo-Subait, K., Ballen, K., Parsons, S., Johns, T., Hahn, T., Sharma, A., Steinbergs, A., D'Souza, A., Kumar, A. J., Yoshimi, A., Wirk, B., Shawl, B., Freytes, C., LeMaistre, C., Bredeson, C., Dandoy, C., Almaguer, D., ... Gergis, U. (2020). Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 26(3), 553-561. https://doi.org/10.1016/j.bbmt.2019.11.003

@article{aae459062dd749b6a91f9def08cd5b7c,

title = "Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research",

abstract = "Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.",

keywords = "adolescent, aya, bone marrow transplantation, cancer survivors, care, childhood, health, intervention, lost to follow-up, outcomes, prevalence, stem cell transplantation, survivor, transition, Bone marrow transplantation, Stem cell transplantation, AYA, PREVALENCE, CARE, CANCER SURVIVORS, ADOLESCENT, HEALTH, INTERVENTION, Survivor, CHILDHOOD, TRANSITION, Lost to follow-up, OUTCOMES",

author = "D. Buchbinder and R. Brazauskas and K. Bo-Subait and K. Ballen and S. Parsons and T. Johns and T. Hahn and A. Sharma and A. Steinbergs and A. D'Souza and A.J. Kumar and A. Yoshimi and B. Wirk and B. Shawl and C. Freytes and C. LeMaistre and C. Bredeson and C. Dandoy and D. Almaguer and D.I. Marks and D. Szwajcer and G. Hale and H. Schouten and H. Hashem and H. Schoemans and H.S. Murthy and H.M. Lazarus and J. Cerny and J. Tay and J.A. Yared and K. Adekola and K.R. Schultz and L. Lehmann and L. Burns and M. Aljurf and M.A. Diaz and N. Majhail and N. Farhadfar and R. Kamble and R. Olsson and R. Schears and S. Seo and S. Beattie and S. Chhabra and B.N. Savani and S. Badawy and S. Ganguly and S. Ciurea and S. Marino and U. Gergis",

note = "Funding Information: Financial disclosure: Dr. Ganguly receives support from Seattle Genetics, Kite Phrama, Janssen Pharmaceuticals, and Daiichi Sankyo. Conflict of interest statement: S.G. receives support from Seattle Genetics, Kite Pharma, Janssen Pharmaceuticals, and Daiichi Sankyo. Financial disclosure: See Acknowledgments on page 560. Funding Information: Financial disclosure: Dr. Ganguly receives support from Seattle Genetics, Kite Phrama, Janssen Pharmaceuticals, and Daiichi Sankyo. Conflict of interest statement: S.G. receives support from Seattle Genetics, Kite Pharma, Janssen Pharmaceuticals, and Daiichi Sankyo. Publisher Copyright: {\textcopyright} 2019 American Society for Transplantation and Cellular Therapy",

year = "2020",

month = mar,

day = "1",

doi = "10.1016/j.bbmt.2019.11.003",

language = "English",

volume = "26",

pages = "553--561",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "3",

}

Buchbinder, D, Brazauskas, R, Bo-Subait, K, Ballen, K, Parsons, S, Johns, T, Hahn, T, Sharma, A, Steinbergs, A, D'Souza, A, Kumar, AJ, Yoshimi, A, Wirk, B, Shawl, B, Freytes, C, LeMaistre, C, Bredeson, C, Dandoy, C, Almaguer, D, Marks, DI, Szwajcer, D, Hale, G, Schouten, H, Hashem, H, Schoemans, H, Murthy, HS, Lazarus, HM, Cerny, J, Tay, J, Yared, JA, Adekola, K, Schultz, KR, Lehmann, L, Burns, L, Aljurf, M, Diaz, MA, Majhail, N, Farhadfar, N, Kamble, R, Olsson, R, Schears, R, Seo, S, Beattie, S, Chhabra, S, Savani, BN, Badawy, S, Ganguly, S, Ciurea, S, Marino, S & Gergis, U 2020, 'Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research', Biology of Blood and Marrow Transplantation, vol. 26, no. 3, pp. 553-561. https://doi.org/10.1016/j.bbmt.2019.11.003

Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. / Buchbinder, D.; Brazauskas, R.; Bo-Subait, K. et al.
In: Biology of Blood and Marrow Transplantation, Vol. 26, No. 3, 01.03.2020, p. 553-561.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors

T2 - A Report from the Center for International Blood and Marrow Transplant Research

AU - Buchbinder, D.

AU - Brazauskas, R.

AU - Bo-Subait, K.

AU - Ballen, K.

AU - Parsons, S.

AU - Johns, T.

AU - Hahn, T.

AU - Sharma, A.

AU - Steinbergs, A.

AU - D'Souza, A.

AU - Kumar, A.J.

AU - Yoshimi, A.

AU - Wirk, B.

AU - Shawl, B.

AU - Freytes, C.

AU - LeMaistre, C.

AU - Bredeson, C.

AU - Dandoy, C.

AU - Almaguer, D.

AU - Marks, D.I.

AU - Szwajcer, D.

AU - Hale, G.

AU - Schouten, H.

AU - Hashem, H.

AU - Schoemans, H.

AU - Murthy, H.S.

AU - Lazarus, H.M.

AU - Cerny, J.

AU - Tay, J.

AU - Yared, J.A.

AU - Adekola, K.

AU - Schultz, K.R.

AU - Lehmann, L.

AU - Burns, L.

AU - Aljurf, M.

AU - Diaz, M.A.

AU - Majhail, N.

AU - Farhadfar, N.

AU - Kamble, R.

AU - Olsson, R.

AU - Schears, R.

AU - Seo, S.

AU - Beattie, S.

AU - Chhabra, S.

AU - Savani, B.N.

AU - Badawy, S.

AU - Ganguly, S.

AU - Ciurea, S.

AU - Marino, S.

AU - Gergis, U.

N1 - Funding Information: Financial disclosure: Dr. Ganguly receives support from Seattle Genetics, Kite Phrama, Janssen Pharmaceuticals, and Daiichi Sankyo. Conflict of interest statement: S.G. receives support from Seattle Genetics, Kite Pharma, Janssen Pharmaceuticals, and Daiichi Sankyo. Financial disclosure: See Acknowledgments on page 560. Funding Information: Financial disclosure: Dr. Ganguly receives support from Seattle Genetics, Kite Phrama, Janssen Pharmaceuticals, and Daiichi Sankyo. Conflict of interest statement: S.G. receives support from Seattle Genetics, Kite Pharma, Janssen Pharmaceuticals, and Daiichi Sankyo. Publisher Copyright: © 2019 American Society for Transplantation and Cellular Therapy

PY - 2020/3/1

Y1 - 2020/3/1

N2 - Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.

AB - Follow-up is integral for hematopoietic cell transplantation (HCT) care to ensure surveillance and intervention for complications. We characterized the incidence of and predictors for being lost to follow-up. Two-year survivors of first allogeneic HCT (10,367 adults and 3865 children) or autologous HCT (7291 adults and 467 children) for malignant/nonmalignant disorders between 2002 and 2013 reported to the Center for International Blood and Marrow Transplant Research were selected. The cumulative incidence of being lost to follow-up (defined as having missed 2 consecutive follow-up reporting periods) was calculated. Marginal Cox models (adjusted for center effect) were fit to evaluate predictors. The 10-year cumulative incidence of being lost to follow-up was 13% (95% confidence interval [CI], 12% to 14%) in adult allogeneic HCT survivors, 15% (95% CI, 14% to 16%) in adult autologous HCT survivors, 25% (95% CI, 24% to 27%) in pediatric allogeneic HCT survivors, and 24% (95% CI, 20% to 29%) in pediatric autologous HCT survivors. Factors associated with being lost to follow-up include younger age, nonmalignant disease, public/no insurance (reference: private), residence farther from the tranplantation center, and being unmarried in adult allogeneic HCT survivors; older age and testicular/germ cell tumor (reference: non-Hodgkin lymphoma) in adult autologous HCT survivors; older age, public/no insurance (reference: private), and nonmalignant disease in pediatric allogeneic HCT survivors; and older age in pediatric autologous HCT survivors. Follow-up focusing on minimizing attrition in high-risk groups is needed to ensure surveillance for late effects. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.

KW - adolescent

KW - aya

KW - bone marrow transplantation

KW - cancer survivors

KW - care

KW - childhood

KW - health

KW - intervention

KW - lost to follow-up

KW - outcomes

KW - prevalence

KW - stem cell transplantation

KW - survivor

KW - transition

KW - Bone marrow transplantation

KW - Stem cell transplantation

KW - AYA

KW - PREVALENCE

KW - CARE

KW - CANCER SURVIVORS

KW - ADOLESCENT

KW - HEALTH

KW - INTERVENTION

KW - Survivor

KW - CHILDHOOD

KW - TRANSITION

KW - Lost to follow-up

KW - OUTCOMES

U2 - 10.1016/j.bbmt.2019.11.003

DO - 10.1016/j.bbmt.2019.11.003

M3 - Article

C2 - 31726205

SN - 1083-8791

VL - 26

SP - 553

EP - 561

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 3

ER -

Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research

Abstract

Keywords

Access to Document

Fingerprint

Cite this